Archives
Homoharringtonine Rapidly Clears SARS-CoV-2 in Preclinical M
2026-05-02
Homoharringtonine Rapidly Clears SARS-CoV-2 in Preclinical Models
Study Background and Research Question
Homoharringtonine is a plant-derived cytotoxic alkaloid long recognized for its efficacy in leukemia research due to its ability to bind the eukaryotic 80S ribosome and inhibit protein synthesis. While its mechanism of inducing G1 phase arrest in leukemic cells is well documented, recent interest has shifted to its potential as an antiviral agent, especially against emerging coronaviruses. The central research question addressed by Wen et al. (2025) is whether homoharringtonine can offer fast, effective viral clearance from the upper respiratory tract during SARS-CoV-2 infection, and if so, whether this could position the compound as a first-line defense in future coronavirus epidemics (paper).Key Innovation from the Reference Study
The pivotal innovation lies in repurposing homoharringtonine—a molecule with a well-characterized cytotoxic mode of action in cancer biology—as a broad-spectrum antiviral. The study demonstrates that homoharringtonine directly blocks protein chain elongation in infected cells, leading to rapid suppression of SARS-CoV-2 replication. Notably, this inhibitory effect was observed at nanomolar concentrations in vitro, highlighting both potency and the mechanistic rationale for targeting viral protein synthesis machinery (paper).Methods and Experimental Design Insights
Wen et al. implemented a multi-tiered experimental pipeline:- In vitro assays assessed SARS-CoV-2 replication in cell cultures exposed to varying concentrations of homoharringtonine, establishing a quantitative dose-response relationship.
- Animal models utilized daily nasal dripping of homoharringtonine (40 μg per dose) in mice post-infection to track viral clearance kinetics in the upper respiratory tract.
- Early clinical evaluation involved two small cohorts. In the first, 26 cancer patients received 1 mg/day by nebulization. In the second, 11 otherwise healthy patients received 0.2 mg/day by repeated nasal spray during an Omicron wave. Viral loads were monitored longitudinally by PCR.
Protocol Parameters
- in vitro SARS-CoV-2 inhibition | nanomolar range | virology/cell culture | Demonstrated potent suppression of viral replication at low concentrations | paper
- animal model nasal administration | 40 μg/day | mouse preclinical | Cleared virus from upper respiratory tract in all treated mice within 3 days | paper
- human nebulization | 1 mg/day | cancer patient cohort | Reduced URT viral load by ~75% within 6 hours post-dosing | paper
- human nasal spray | 0.2 mg/day | mild COVID-19, Omicron wave | Cleared virus in 10/11 patients within 2–4 days; typically requires 7–9 days without intervention | paper
- compound storage | -20°C | all research settings | Maintains stability and activity | product_spec
- compound solubility | ≥10.92 mg/mL in ethanol, ≥181.2 mg/mL in DMSO | solution preparation | Facilitates formulation for in vitro and in vivo use | product_spec
Core Findings and Why They Matter
The study's central finding is the rapid, robust antiviral effect of homoharringtonine against SARS-CoV-2 across three models:- In vitro, homoharringtonine completely suppressed replication of SARS-CoV-2 and other coronaviruses at nanomolar concentrations (paper).
- In mice, daily nasal application cleared the virus from the upper respiratory tract in all animals within three days (paper).
- In two small clinical cohorts, both nebulized and nasal spray delivery led to rapid viral load reduction—often achieving PCR negativity in 2–4 days compared with 7–9 days in untreated populations (paper).